ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?

AbbVie expects 2026 revenue growth of about 10%, supported by Skyrizi and Rinvoq sales expected to exceed $31 billion combined and grow more than 20%; their first-half sales rose 26.3% and 22.2%, respectively. Growth in neuroscience, including $457 million of first-half Vyalev sales, new FDA approval for Juvmo, and pipeline/M&A progress underpin the post-Humira outlook. Offsetting factors include a 38.2% first-half decline in Humira sales, 2.4% Q2 oncology-sales decline, flat $5 billion aesthetics outlook, intensified Skyrizi competition, and modest 2026-27 EPS estimate reductions; the article maintains a Hold rating.

Analysis

ABBV’s rerating is increasingly dependent on sustaining immunology volume growth rather than simply offsetting legacy-product erosion. That raises the importance of weekly prescription/share data in psoriasis and IBD: a modest share loss to JNJ’s oral entrant could matter disproportionately because ABBV’s premium multiple now embeds durable double-digit growth from its two core franchises. The estimate cuts despite the stock advance suggest sell-side models are already absorbing pricing and acquisition-related margin pressure, creating a narrower upside/downside skew over the next 1-3 months.

JNJ is the most relevant competitive beneficiary if oral psoriasis adoption broadens beyond biologic-naive patients; the larger strategic implication is that payer step-edit policies could migrate into adjacent immunology indications, reducing switching friction for competing mechanisms. ABBV’s neuroscience portfolio diversifies this risk, but launch curves for Parkinson’s therapies are coverage- and physician-training-dependent, so early sales should not be extrapolated linearly into peak-sales assumptions. Pipeline readouts over the next several months can support the 6-18 month growth narrative, but they are unlikely to offset a near-term deceleration in Skyrizi/Rinvoq net-price realization.

Contrarian view: ABBV is no longer a clean post-patent-cliff recovery trade after its recent outperformance; it is a quality compounder priced closer to execution perfection than the headline sector-relative multiple implies. The more attractive entry is on a prescription, pricing, or aesthetics-driven miss that leaves the long-duration immunology/neuroscience thesis intact. Falsification is two consecutive quarters of material Skyrizi/Rinvoq growth deceleration, a guidance reduction, or evidence that JNJ captures meaningful psoriasis share without offsetting IBD gains.

Key Decisions for Investors

• Maintain ABBV as a core but do not add aggressively after the rerating; target additions only on a 8-12% pullback or after quarterly data confirm combined immunology growth remains above 20%. Risk: further estimate cuts compress the multiple toward its historical range; reward: 12-18 month earnings visibility from immunology and neuroscience.
• Initiate a 3-6 month relative-value position: long ABBV / short JNJ in equal beta-adjusted size only if ABBV demonstrates stable U.S. prescription share through the next earnings report. Exit if JNJ’s psoriasis launch shows accelerating formulary wins or ABBV lowers immunology guidance.
• Use the next ABBV earnings event as a monitoring catalyst rather than an outright options trade: track net pricing, new-to-brand prescriptions, and management commentary on payer access. A revenue beat driven solely by inventory, FX, or acquired revenue without share data is not thesis-confirming.
• Avoid treating APGE as a standalone catalyst from the reported transaction until consideration, closing conditions, and pipeline economics are independently verified; any integration-related R&D charge or dilution would be a near-term ABBV margin headwind rather than an immediate source of upside.